Advertisement

Commentary: Old Data Provide New Insights into the Therapeutic Benefit of Adjuvant Chemotherapy in Non-Small Cell Lung Cancer

  • Kyle G. Mitchell
    Affiliations
    Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030
    Search for articles by this author
  • Mara B. Antonoff
    Correspondence
    Address reprint requests to Mara B. Antonoff, MD, Associate Professor, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA 77030, Phone: 713-563-3100; Fax: 713-794-4901
    Affiliations
    Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030
    Search for articles by this author
Published:November 15, 2022DOI:https://doi.org/10.1053/j.semtcvs.2022.11.006
      Analysis of the JBR10 trial demonstrates a larger survival benefit associated with adjuvant chemotherapy than previously understood, providing a benchmark as novel adjuvant therapies are explored.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pignon J.P.
        • Tribodet H.
        • Scagliotti G.V.
        • et al.
        Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
        J Clin Oncol. 2008; 26: 3552-3559
        • Toubat O.
        • Atay S.M.
        • Kim A.W.
        • et al.
        Disparities in Guideline-Concordant Treatment for Pathologic N1 Non-Small Cell Lung Cancer.
        Ann Thorac Surg. 2020; 109: 1512-1520
      1. Toubat O.D.L., Ding K., et al. Benefit of Adjuvant Chemotherapy for Resected Pathologic N1 Non-Small Cell Cancer Is Unrecognized: A Subgroup Analysis of the JBR10 Trial. Semin Thorac Cardiovasc Surg. In press.

        • Winton T.
        • Livingston R.
        • Johnson D.
        • et al.
        Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
        N Engl J Med. 2005; 352: 2589-2597
        • Wu Y.L.
        • Tsuboi M.
        • He J.
        • et al.
        Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
        N Engl J Med. 2020; 383: 1711-1723
        • Felip E.
        • Altorki N.
        • Zhou C.
        • et al.
        Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
        Lancet. 2021; 398: 1344-1357

      Linked Article